Core Insights - Calidi Biotherapeutics has selected IL15 superagonist as the first payload for its RTNova platform, aimed at delivering targeted antitumor virotherapies into tumors [1][2] - The RTNova platform utilizes a modified vaccinia virus designed for systemic administration, allowing it to reach metastatic tumor sites and activate immune responses while destroying cancer cells [2][4] - Preclinical data presented at the AACR Annual Meeting indicates that the enveloped virotherapy significantly increases complete tumor responses after a single systemic administration [2][3] Company Overview - Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel therapies that enhance the immune system's ability to combat cancer [6] - The company employs proprietary stem cell-based platforms to deliver oncolytic viruses, targeting various oncology indications, including high-grade gliomas and solid tumors [6] - Calidi's approach aims to improve the efficacy and safety of cancer treatments by utilizing allogeneic stem cells to carry therapeutic payloads [6]
Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting